tetano
Editor, Senior Moderator
J Eur Acad Dermatol Venereol
. 2020 Aug 11.
doi: 10.1111/jdv.16863. Online ahead of print.
Concerns related to the COVID-19 pandemic in adult patients with atopic dermatitis and psoriasis treated with systemic immunomodulatory therapy: a Danish questionnaire survey
Nikolai Dyrberg Loft[SUP] 1 2 [/SUP], Anne-Sofie Halling[SUP] 1 2 [/SUP], Lars Iversen[SUP] 3 [/SUP], Christian Vestergaard[SUP] 3 [/SUP], Mette Deleuran[SUP] 3 [/SUP], Mads Kirchheiner Rasmussen[SUP] 3 [/SUP], Claus Zachariae[SUP] 1 2 [/SUP], Jacob P Thyssen[SUP] 1 2 [/SUP], Lone Skov[SUP] 1 2 [/SUP]
Affiliations
Abstract
Patients with moderate-to-severe atopic dermatitis (AD) or psoriasis often require systemic immunomodulatory therapy. The uncertainty of the potential of these therapies to increase the risk of more serious illness due to Coronavirus disease 2019 (COVID-19) may have caused anxiety and led to treatment discontinuation. Therefore, we conducted an anonymous questionnaire on concerns of COVID-19 in patients with AD or psoriasis treated with systemic immunomodulatory therapy.
Keywords: Atopic dermatitis; Biologics; COVID-19; Patient reported outcomes; Psoriasis; Systemics.
. 2020 Aug 11.
doi: 10.1111/jdv.16863. Online ahead of print.
Concerns related to the COVID-19 pandemic in adult patients with atopic dermatitis and psoriasis treated with systemic immunomodulatory therapy: a Danish questionnaire survey
Nikolai Dyrberg Loft[SUP] 1 2 [/SUP], Anne-Sofie Halling[SUP] 1 2 [/SUP], Lars Iversen[SUP] 3 [/SUP], Christian Vestergaard[SUP] 3 [/SUP], Mette Deleuran[SUP] 3 [/SUP], Mads Kirchheiner Rasmussen[SUP] 3 [/SUP], Claus Zachariae[SUP] 1 2 [/SUP], Jacob P Thyssen[SUP] 1 2 [/SUP], Lone Skov[SUP] 1 2 [/SUP]
Affiliations
- PMID: 32780487
- DOI: 10.1111/jdv.16863
Abstract
Patients with moderate-to-severe atopic dermatitis (AD) or psoriasis often require systemic immunomodulatory therapy. The uncertainty of the potential of these therapies to increase the risk of more serious illness due to Coronavirus disease 2019 (COVID-19) may have caused anxiety and led to treatment discontinuation. Therefore, we conducted an anonymous questionnaire on concerns of COVID-19 in patients with AD or psoriasis treated with systemic immunomodulatory therapy.
Keywords: Atopic dermatitis; Biologics; COVID-19; Patient reported outcomes; Psoriasis; Systemics.